Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Aug 14, 2025; 31(30): 110112
Published online Aug 14, 2025. doi: 10.3748/wjg.v31.i30.110112
Table 2 Comparison of demographic characteristics, clinical and laboratory findings between relapse and non-relapse groups, n (%)
Characteristics
Relapse (n = 12) (40.0%)
Non-relapse (n = 18) (60.0%)
P value
Age at onset of IBD (years), median (IQR)31.0 (21.5-34.8)31.5 (22.0-37.8)0.5451
Female/male4 (33.3)/8 (66.7)9 (50.0)/9 (50.0)0.3672
Smoking status
Current-smokers3 (25.0)4 (22.2)0.9993
Ex-smokers3 (25.0)5 (27.8)
Non-smokers6 (50.0)9 (50.0)
Family history of IBD3 (25.0)3 (16.7)0.6603
BMI (kg/m2), median (IQR)23.2 (20.3-25.8)23.7 (20.4-31.6)0.6391
Total disease duration (months), median (IQR)193.5 (89.3-270.8)167.5 (69.5-237.5)0.4651
Duration of remission before 5-ASA treatment withdrawal (months), median (IQR)152.0 (26.0-206.5)122.0 (15.3-172.3)0.3911
Follow-up time from 5-ASA withdrawal (months), median (IQR)23.5 (14.3-67.3)29.0 (17.3-61.3)0.6021
Disease extension
Proctitis3 (25.0)3 (16.7)0.6003
Left-sided UC7 (58.3)14 (77.8)
Extensive UC2 (16.7)1 (5.6)
Extra-intestinal manifestations5 (41.7)9 (50.0)0.6542
Previous medications
5-ASA tablet9 (75.0)16 (88.9)0.6223
5-ASA granule2 (16.7)0 (0.0)0.1523
5-ASA enema7 (58.3)11 (61.1)0.9993
5-ASA suppository2 (16.7)3 (16.7)0.9993
Sulfasalazine1 (8.3)0 (0.0)0.4003
Steroids6 (50.0)3 (16.7)0.1023
Thiopurine2 (16.7)1 (5.6)0.5483
Biologic agents1 (8.3)1 (5.6)0.9993
Steroid dependence2 (16.7)1 (5.6)0.5483
Withdrawal 5-ASA formula
5-ASA tablet9 (75.0)16 (88.9)0.3643
5-ASA granule2 (16.7)0 (0.0)0.1523
5-ASA enema7 (58.3)11 (61.1)0.9993
5-ASA suppository2 (16.7)4 (22.2)0.9993
Baseline CRP (mg/L), median (IQR)5.0 (5.0-5.0)5.0 (4.2-5.0)0.9171
Hemoglobin (g/dL), median (IQR)13.0 (12.0-13.0)13.0 (12.0-13.7)0.4191
Albumin (g/dL), median (IQR)4.0 (4.0-4.0)4.0 (4.0-4.5)0.1091
Baseline eMayo subscore, median (IQR)1.0 (1.0-1.8)1.0 (1.0-1.3)0.8191
Baseline pMayo score, median (IQR)5.0 (5.0-5.0)5.0 (4.2-5.0)0.6621